Colorectal Neoplasm Clinical Trial
Official title:
Safety and Efficacy of Reduced-port Laparoscopic Surgery for Patients Of Colon and Upper Rectal Cancer --an Open Label, Multicenter, Prospective Phase Ⅱ Study
Colorectal cancer is the third most common malignant tumor. Radical resection is the mainstay of treatments for non-metastatic colorectal cancer. In case of traditional laparoscopic surgery, inexperienced assistants are likely to cause side injuries and interfere surgeon due to limited operating space. Reduced-port laparoscopic surgery has only 3 ports for surgeon and observer, and the surgeon completes the surgery independently, which increases the difficulty of the operation. However, reduced-port laparoscopy has some potential advantages and applications. Reduced-port laparoscopic surgery avoids the prolongation of the operation time and parainjury caused by inexperienced assistant. Reduced-port laparoscopy reduces some surgical incisions, resulting in less pain and faster recovery. Reduced-port laparoscopy also reduces the consumables, human resources and medical expenses. This study aims to evaluate the curative effect and safety of reduced-port laparoscopic surgery versus conventional laparoscopic surgery for resectable colorectal cancer.
Status | Recruiting |
Enrollment | 500 |
Est. completion date | April 1, 2026 |
Est. primary completion date | April 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Age 18-80 years old; 2. Pathological diagnosis of colorectal adenocarcinoma (including high, medium and low-differentiated adenocarcinoma, excluded: mucinous adenocarcinoma, signet ring cell carcinoma); 3. Eastern Cooperative Oncology Group (ECOG) is 0-1 points; 4. Chest, whole abdomen, pelvic enhanced CT confirm colon or upper rectal cancer, without distant metastasis; 5. No other multiple primary tumors; 6. No organ dysfunction; 7. The patient and his/her family are able to understand the study protocol and are willing to participate in the study and sign informed consent. Exclusion Criteria: 1. Age < 18, or > 80 years old; 2. Combined with simultaneous or heterogeneous (within 5 years) malignant tumors; 3. Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, etc. who require emergency surgery; 4. Joint organ resection is required; 5. ASA Class IV or V; 6. Suffering from a serious mental illness; 7. Patients with severe emphysema, interstitial pneumonia or ischemic heart disease, etc. who cannot tolerate surgery; 8. Continuous systemic steroid therapy within 1 months; 9. Patients or families are unable to understand the conditions and objectives of this study. |
Country | Name | City | State |
---|---|---|---|
China | The Sixth Affiliated Hospital, Sun Yatsen University | Guangzhou | Guangdong |
Lead Sponsor | Collaborator |
---|---|
Sixth Affiliated Hospital, Sun Yat-sen University |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | DFS rate | Disease-free survival rate | 1 year | |
Secondary | Total opertaion time | Time from surgery started to surgery ended | through opertation completion, an average of 2 hours | |
Secondary | Intraoperative blood loss | Blood loss during operation | through study completion, an average of 50 ml | |
Secondary | Postoperative hospital stay | Day from operation finished to patient discharged | through anticipants discharged, an average of 7 days | |
Secondary | Postoperative complication rate | Any complication associated with operation based on Clavien-Dindo classification | 30 days | |
Secondary | Postoperative mortality | Death associated with operation | 30 days | |
Secondary | 3 years DFS Rate | Disease-free survival rate | 3 years | |
Secondary | 3 years OS Rate | Overall survival rate | 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02244632 -
Modufolin (Arfolitixorin) in Combination With 5-Fluorouracil Alone or Together With Oxaliplatin or Irinotecan in Colorectal Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01417611 -
The Usefulness of I-scan in Screening Colonoscopy
|
N/A | |
Completed |
NCT02057471 -
Intravenous Iron: Measuring Response in Anemic Surgical Patients
|
Phase 4 | |
Terminated |
NCT01074333 -
An Observational Study of Erbitux® in Patients With Metastatic Colorectal Cancer (mCRC) Refractory to Irinotecan-containing Treatment
|
N/A | |
Active, not recruiting |
NCT00506207 -
A Phase I Study of S-1 Plus Irinotecan and Oxaliplatin in Advanced Gastrointestinal Malignancy
|
Phase 1 | |
Completed |
NCT01959269 -
Investigating the Use of Regorafenib (Stivarga®) in Patients With Metastatic Colorectal Cancer (mCRC) After Failure of Standard Therapy
|
N/A | |
Completed |
NCT03559543 -
Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT04160832 -
Prevalence and Spectrum of Cancer Susceptibility Among Patients With Advanced Colorectal Polyps
|
||
Terminated |
NCT02961283 -
Study of ASN003 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Suspended |
NCT02121405 -
Randomized Trial of Primary Surgery Followed Selective Radiochemotherapy for Rectal Cancer With MRI Negative CRM
|
Phase 3 | |
Active, not recruiting |
NCT03936530 -
Infrapyloric and Greater Curvature Lymph Node Metastasis in Colon Cancer
|
||
Terminated |
NCT03724071 -
Study of TG6002 (VV TK-RR-FCU1) in Combination With 5-FC in Patients With Advanced Gastro-intestinal Tumors.
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02882620 -
Enhancing Prevention Pathways Toward Tribal Colorectal Health
|
N/A | |
Completed |
NCT00906997 -
Colorectal Cancer Screening in Average-risk Population: Immunochemical Fecal Occult Blood Testing Versus Colonoscopy
|
N/A | |
Completed |
NCT00188331 -
Cognitive Function and Fatigue in Colorectal Cancer (CRC) Patients After Chemotherapy
|
N/A | |
Completed |
NCT04786704 -
A Stool DNA Test for Detection of Advanced Colorectal Neoplasia in Asymptomatic Chinese Community Population
|
||
Terminated |
NCT02384850 -
Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
|
Phase 1 | |
Completed |
NCT01288833 -
Clinical Study of Real Time Colorectal Polyp Diagnosis During Colonoscopy - the VALID Colonoscopy Study
|
N/A | |
Completed |
NCT00001693 -
Phase I-II Multiple-Dose Safety and Efficacy Study of a Selective Inhibitor of Cyclooxygenase - 2 (SC-58635) in Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Patients and Carriers
|
Phase 1 | |
Recruiting |
NCT03280407 -
NEOadjuvant Chemotherapy Only Compared With Standard Treatment for Locally Advanced Rectal Cancer
|
Phase 2 |